Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Johnny Kao
- Target Recruit Count
- 33
- Registration Number
- NCT00462735
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 7
- Registration Number
- NCT00448097
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 36
- Registration Number
- NCT00444678
- Locations
- 🇺🇸
New York University Langone Medical Center, New York, New York, United States
🇺🇸Bellevue Hospital, New York, New York, United States
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT00437268
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubbock, Texas, United States
ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 46
- Registration Number
- NCT00436072
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- PD Dr. med. Volker Heinemann
- Target Recruit Count
- 568
- Registration Number
- NCT00433927
- Locations
- 🇩🇪
University of Munich - Klinikum Grosshadern, Munich, Germany
Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 8
- Registration Number
- NCT00430027
- Locations
- 🇺🇸
University of Colorado at Denver and Health Science Center, Aurora, Colorado, United States
Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2009-02-27
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 21
- Registration Number
- NCT00422773
- Locations
- 🇩🇪
Universitaetsklinik Mannheim GmbH, III. Medizinische Klinik, Mannheim, Germany
🇩🇪Universitaetsklinikum Carl Gustav Carus, Medizinische Klinik, Dresden, Sachsen, Germany
🇩🇪Westdeutsches Tumorzentrum, Universitaetsklinikum Essen, Essen, Germany
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00409565
- Locations
- 🇺🇸
UPMC / UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 64
- Registration Number
- NCT00408499
- Locations
- 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.